Interferon alpha kinoid

Drug Profile

Interferon alpha kinoid

Alternative Names: Antiferon; IFN-K - Neovacs; IFNα kinoid

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Neovacs
  • Developer Neovacs; sanofi pasteur
  • Class Interferons; Vaccines
  • Mechanism of Action Immunomodulators; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 01 Mar 2017 Interferon alpha kinoid is available for licensing in USA, Europe as of 22 Feb 2017. http://neovacs.fr/en/
  • 21 Feb 2017 Biosense Global enters into license option agreement with Neovacs for Interferon alpha kinoid for Systemic lupus erythematosus and Dermatomyositis in China, Macau, Hong Kong, Taiwan and Singapore
  • 09 Feb 2017 Neovacs has patent protection for Interferon alpha kinoid in China, with pending applications in major markets worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top